-
Posted by
Two Blokes Jul 4 -
Filed in
Stock
-
6 views
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only immunotherapy authorised in Europe for use both before and after surgery, what doctors call “perioperative” treatment, in patients whose cancer has spread into the bladder muscle but is still operable.
